Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
Side-by-side · Research reference

DSIPvsSemax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited
BHuman-MechanisticDraft12/39 cited
DSIP
Sleep modulator · Anti-stress
100–200 mcgPer doseSchneider 1986
HumanMechanisticSchneider 1986
HoursHalf-life (est)
SQ · Pre-sleep · Daily during cycle
Semax
Cognitive enhancer · Russian Pharma
200–600 mcg/doseIntranasalKaplan 2017
HumanMechanisticKaplan 2017
~30 minOnset
Intranasal · 2–3×/day during cognitive demand

01Mechanism of Action

Parameter
DSIP
Semax
Primary target
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
BDNF / NGF expression + monoamine modulationKaplan 2017
Pathway
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017
Downstream effect
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017
Feedback intact?
Origin
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017
Antibody development

02Dosage Protocols

Parameter
DSIP
Semax
Standard dose
100–200 mcg SQ pre-sleepSchneider 1986
200–600 mcg / dose intranasalKaplan 2017
Frequency
Once daily, pre-sleep
2–3× per day during cognitive demand
Lower / starter dose
50 mcg pre-sleep
100 mcg / dose
Evidence basis
Human-mechanistic + early clinicalSchneider 1986
Human-mechanistic + Russian clinicalKaplan 2017
Duration
8–12 weeks per cycle
10–14 day cycles, repeated PRN
Reconstitution
Bacteriostatic water
Pre-formulated nasal spray (commercial); research vial: bacteriostatic water
Timing
30–60 min pre-sleep
Morning + early afternoon
Half-life
Short plasma; CNS effects last hours
Short plasma; CNS effect lasts ~3–6 hr

04Side Effects & Safety

Parameter
DSIP
Semax
Injection site reaction
Mild irritation
Drowsiness
Expected effect (intentional)
Vivid dreams
Anecdotally reported
Long-term safety
Limited modern RCT data
Limited Western RCT data
Pregnancy / OB
Avoid
Avoid
Nasal irritation
Mild burning or congestion (transient)
Sleep disruption
Late-day dosing may interfere with sleep
Headache
Uncommon, transient
Absolute Contraindications
DSIP
  • ·Pregnancy / breastfeeding
  • ·Concurrent CNS-depressant therapy without supervision
Semax
  • ·Pregnancy / breastfeeding
Relative Contraindications
DSIP
  • ·Severe sleep apnoea (untreated)
  • ·Concurrent benzodiazepine / opioid use
Semax
  • ·Active psychiatric instability
  • ·Concurrent strong stimulants

05Administration Protocol

Parameter
DSIP
Semax
1. Reconstitution
Add 1–2 mL bacteriostatic water to vial.
Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.
2. Injection site
SQ — abdomen. Rotate sites.
Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.
3. Timing
30–60 min pre-sleep.
Morning + early afternoon. Avoid evening (sleep disruption).
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Refrigerate after reconstitution; light-protected.
5. Needle
29–31G insulin syringe.
Cycle on/off to avoid neurochemical adaptation.

06Stack Synergy

DSIP
— no documented stacks
Semax
+ Selank
Moderate
View Selank

Semax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.

Semax
200–600 mcg intranasal · morning + afternoon
Selank
150–300 mcg intranasal · midday + early evening
Primary benefit
Cognitive enhancement + stress mitigation